U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07219368) titled 'A First-in-Human Single and Multiple Ascending Dose Study of MT-201' on Oct. 17.
Brief Summary: First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.
Study Start Date: Oct. 08
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer
Intervention:
DRUG: MT-201
MT-201
DRUG: Placebo
Placebo
Recruitment Status: RECRUITING
Sponsor: Mirador Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....